Skip to main content
Alzheimer's ResearchJohns Hopkins University· 7 min read· in Science

Brain Region Atrophy Detectable a Decade Before Clinical Alzheimer's Emerges

Johns Hopkins researchers have identified structural shrinkage in the entorhinal cortex and amygdala that precedes memory loss by up to ten years. The discovery offers a potential new biomarker for early intervention in Alzheimer's disease.

By Viktoria Sokolova

Share this story

Listen

Medical researchers have identified structural deterioration in two specific brain regions that precedes clinical Alzheimer's disease symptoms by up to a decade. The discovery shifts the focus of early detection away from the hippocampus, the area traditionally examined for cognitive decline.[1][2]

Scientists at Johns Hopkins University analyzed hundreds of magnetic resonance imaging and positron emission tomography scans to track tissue volume over time. They found that the entorhinal cortex and the amygdala begin shrinking years before memory loss becomes apparent to patients or their families.[1]

The findings offer a potential structural biomarker that could identify at-risk individuals long before irreversible cognitive damage occurs. This early warning window could eventually allow therapeutic interventions to begin when they have the highest probability of preserving brain function.[2][3]

Beyond the hippocampus

The entorhinal cortex functions as a critical hub for retrieving previously stored memories, while the amygdala processes and stores emotional experiences. Both structures sit adjacent to the hippocampus, which has historically served as the primary focal point for Alzheimer's assessments.[2][4]

Historically, clinical assessments of Alzheimer's disease have relied heavily on measuring hippocampal volume, as memory impairment is the most recognizable hallmark of the condition. By the time hippocampal shrinkage becomes obvious on a scan, the patient has typically already experienced significant cognitive decline.[1]

Across multiple stages of cognitive health, the research team observed a consistent pattern of tissue loss in these two adjacent regions. The atrophy in the entorhinal cortex and amygdala outpaced the deterioration seen in the hippocampus during the preclinical phases of the disease.[1][4]

Structural changes in specific brain regions outpace hippocampal deterioration during the preclinical phase of the disease.

"We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms," said Michael Miller, a biomedical engineer and senior author of the study at Johns Hopkins University.[1][2]

Miller emphasized the therapeutic potential of this extended timeline. "It's at least a 5-to-10-year play where your brain is changing. Imagine if we could start to treat the neurodegenerative changes at the 2, 3 or 4-year point rather than after 15 years when the changes are manifesting in memory symptoms," he said.[1][2]

The structural changes were documented in a September 2026 paper published in Volume 6, Issue 3 of the journal NeuroImage: Reports. The research team also presented their data at Neuroscience 2026, the annual meeting of the Society for Neuroscience.[1][4]

Tracking longitudinal decline

To validate the atrophy timeline, the investigators drew upon two large-scale independent datasets: the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. These cohorts provided a robust baseline for tracking structural shifts.[2][4]

These longitudinal cohorts provided hundreds of brain scans collected over several years, tracking more than 1,000 individuals who were initially symptom-free. The sample included participants who maintained normal cognition, those who developed mild cognitive impairment, and patients who died from Alzheimer's disease.[1][4]

High-field atlasing techniques allowed the researchers to map specific subregions within the amygdala. They discovered that volume loss was predominantly concentrated in the medial subregions—including the basomedial, basolateral, and corticocentromedial areas—rather than the lateral amygdala.[4]

The researchers also utilized surface-based diffeomorphic reconstructions to measure cortical laminar thinning across more than 400 samples. This approach confirmed that the overall volume loss observed in the entorhinal cortex corresponded directly to the thinning of specific cortical layers, validating the MRI measurements.[4]

Illustration: The structural shrinkage observed on MRI scans strongly correlates with the accumulation of abnormal tau proteins.

The integration of positron emission tomography allowed the researchers to cross-reference these structural deficits with metabolic and molecular activity. This multimodal imaging approach provided a comprehensive view of how physical shrinkage correlates with the underlying chemical imbalances driving the neurodegeneration.[4]

By comparing the trajectories of patients who progressed to dementia against those who remained cognitively stable, the team isolated the specific structural changes tied to the disease. The divergence in tissue volume between the two groups became statistically significant years before standard cognitive tests registered any decline.[4]

The tau protein connection

The structural shrinkage observed on MRI scans aligns with the known molecular pathology of Alzheimer's disease, specifically the accumulation of abnormal tau proteins. Under healthy conditions, tau helps maintain the internal scaffolding of nerve cells.[2][3]

In Alzheimer's disease, tau proteins misfold and clump together to form neurofibrillary tangles, which disrupt cellular function and lead to cell death. The Johns Hopkins team used PET imaging and digital pathology to map the spatial distribution of this tau burden across the brain.[1][2]

They demonstrated a strong spatial correlation between the areas of gray matter atrophy and the zones of heavy tau accumulation. The regions experiencing the most severe tissue loss in the entorhinal cortex and medial amygdala perfectly mirrored the known histopathological distribution of tau tangles.[1][4]

Gray matter contains the dense concentrations of nerve cell bodies required for processing information. The overlapping presence of tau pathology and gray matter shrinkage strengthens the case that these structural changes are direct consequences of the disease process rather than normal aging.[2][4]

"Our future work is to better show the molecular neighborhoods associated with these Tau protein changes as localized by these clinical biomarkers of atrophy," Miller noted, adding that understanding these cellular environments is a prerequisite for developing targeted therapies.[1][2]

Volume loss in the entorhinal cortex and medial amygdala becomes statistically significant years before standard cognitive tests register decline.

Shifting the diagnostic timeline

The identification of these early structural biomarkers could fundamentally alter how clinicians screen for neurodegenerative diseases. As brain scanning technology becomes more affordable and widely available, baseline assessments could be conducted much earlier in life.[1]

For individuals carrying genetic risk factors or those with a family history of dementia, physicians might initiate targeted MRI screening when patients are in their 30s and 40s. This proactive approach would establish a structural baseline to measure future tissue loss against.[1][2]

"As biomarkers and treatments become increasingly available, knowing who is going to have cognitive decline is going to be really important," said Meaghan Morris, a neuropathologist and co-author of the study who specializes in Alzheimer's and other dementias.[1][2]

Morris highlighted the clinical utility of the findings for patient management. "This could really play into better risk stratification for identifying who is going to have cognitive decline in the near future—and treating people earlier and earlier to hopefully slow the course of the disease," she explained.[1][2]

While the current findings provide a robust framework for understanding disease progression, the researchers caution that measuring amygdala and entorhinal cortex volume is not yet a standalone clinical diagnostic test. Further validation across broader populations remains necessary before widespread implementation.[3]

Preparing for early interventions

The shift toward early detection aligns with the broader trajectory of Alzheimer's research, which increasingly views the condition as a decades-long process. The failure of many late-stage drug trials has driven the field to seek interventions before widespread neuronal death occurs.[1]

Illustration: Targeted MRI screening in asymptomatic individuals could eventually establish a structural baseline to measure future tissue loss against.

If clinicians can reliably identify the disease during its silent phase, pharmaceutical companies could test disease-modifying therapies in populations whose brain architecture remains largely intact. The entorhinal cortex and amygdala measurements provide a quantifiable endpoint for such trials.[1][4]

Current clinical trials often struggle to recruit patients at the optimal stage for intervention, as identifying asymptomatic individuals with underlying pathology remains difficult. A reliable structural biomarker could streamline the screening process, ensuring that experimental drugs are tested on patients who stand to benefit the most.[1][2]

The next phase of the Johns Hopkins research will focus on the precise molecular mechanisms driving tissue loss in these vulnerable regions. By decoding the interaction between tau accumulation and cellular death, the team hopes to identify new targets for drugs that could halt the atrophy.[1][2]

Key points

  1. Johns Hopkins researchers discovered that the entorhinal cortex and amygdala shrink up to a decade before Alzheimer's memory symptoms appear.
  2. The structural deterioration in these two regions outpaces volume loss in the hippocampus during the preclinical stages of the disease.
  3. Areas of severe gray matter atrophy strongly correlate with the accumulation of abnormal tau protein tangles.
  4. Early detection through targeted MRI screening could allow therapeutic interventions to begin years before irreversible cognitive damage occurs.

What we don’t know

  • Whether measuring entorhinal cortex and amygdala volume can serve as a standalone clinical diagnostic test without complementary fluid biomarkers.
  • The exact molecular mechanisms that make the medial subregions of the amygdala particularly vulnerable to early tau accumulation.
Diagnostic Researchers 60%Clinical Neurologists 40%
Diagnostic Researchers
Scientists focused on identifying early structural and molecular biomarkers to improve risk stratification.
Clinical Neurologists
Medical professionals focused on translating structural findings into actionable patient care and early intervention strategies.

Perspectives this story doesn't cover

  • Patients with a family history of early-onset Alzheimer's
  • Health insurance providers evaluating the cost-effectiveness of early MRI screening

Sources

Source coverage

4 outlets

2 viewpoints surfaced

Diagnostic Researchers 60%Clinical Neurologists 40%
  1. [1]EurekAlert!Diagnostic Researchers

    Researchers pinpoint earlier evidence of Alzheimer's

    Read on EurekAlert! →
  2. [2]ScienceDailyDiagnostic Researchers

    Alzheimer's may start shrinking two brain regions years before memory loss

    Read on ScienceDaily →
  3. [3]The News InternationalClinical Neurologists

    Scientists identify major brain changes that may reveal Alzheimer's a decade early

    Read on The News International →
  4. [4]NeuroImage: ReportsDiagnostic Researchers

    Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum

    Read on NeuroImage: Reports →
Listen

Comments

Stay informed

Every angle. Every day.

Get Science stories with full source coverage and perspective breakdowns, free every day.